Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2010
10/19/2010CA2178396C Enhancing keratinocyte migration and proliferation with clostridiopeptidase-a-collagenase
10/15/2010WO2009126950A2 Diterpene glycosides as natural solubilizers
10/15/2010CA2758122A1 Diterpene glycosides as natural solubilizers
10/14/2010WO2010118330A2 Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
10/14/2010WO2010118298A2 Compositions and methods for bioactive coatings to improve allograft incorporation
10/14/2010WO2010117090A1 Novel isoquinolinyloxymethyl heteroaryl derivatives
10/14/2010WO2010117085A1 Aryl indole derivatives
10/14/2010WO2010117084A1 Novel isoquinoline derivatives
10/14/2010WO2010117055A1 Polypeptide having selective inhibitory activity on protein kinase cα or η
10/14/2010WO2010117040A1 Five-membered heterocyclic compound
10/14/2010WO2010117014A1 Triazine derivative
10/14/2010WO2010116899A1 Phosphorylation-inhibiting agent or dephosphorylating agent for pten
10/14/2010WO2010116760A1 Inhibitor for elevation of gip level
10/14/2010WO2010116673A1 Mitochondrial function-improving agent
10/14/2010WO2010115629A2 Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
10/14/2010US20100263066 Inert dna sequences for efficient viral packaging and methods of use
10/14/2010US20100261785 Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s)
10/14/2010US20100261767 Oxadiazole derivatives for use as s1p1 agonists in the treatment of autoimmune and inflammatory disorders
10/14/2010US20100261720 Heterocyclic compound and pharmaceutical composition thereof
10/14/2010US20100261718 N3 alkylated benzimidazole derivatives as mek inhibitors
10/14/2010US20100261717 N3 alkylated benzimidazole derivatives as mek inhibitors
10/14/2010US20100261650 Recombinant fusion proteins to growth hormone and serum albumin
10/14/2010US20100261641 Spiro-piperidine compounds and medicinal use thereof
10/14/2010US20100261273 Mammalian Receptor Proteins; Related Reagents and Methods
10/14/2010US20100260858 Drug delivery composition
10/14/2010US20100260850 Controlled Release Devices and Methods for Delivery of Nucleic Acids
10/14/2010US20100260847 Tissue matrices comprising placental stem cells
10/14/2010US20100260815 Fluid concentrator, autologous concentrated body fluids, and uses thereof
10/14/2010US20100260780 Uniform field magnetization and targeting of therapeutic formulations
10/14/2010US20100260776 Therapeutic method for reducing angiogenesis
10/14/2010US20100260747 Use of Tetrahydrobiopterin as a Marker and a Therapeutic Agent for Fabry Disease
10/14/2010US20100260740 Methods for preventing and/or treating lysosomal storage disorders
10/14/2010US20100260714 Compositions comprising n3 alkylated benzimidazole derivatives as mek inhibitors and methods of use thereof
10/14/2010US20100260696 Aqueous Compositions Containing Alkoxylated Phosphoric Acid Triesters
10/14/2010US20100260683 Thermolabile liposome with controlled release temperature
10/14/2010US20100260678 Anti-igf-i receptor antibodies
10/14/2010DE202010010227U1 Mittel zum Entfernen von Zecken von einer Einstichstelle auf der menschlichen oder tierischen Haut Means for removing ticks from a puncture site on the human or animal skin
10/14/2010CA2758201A1 Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
10/14/2010CA2756272A1 Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
10/13/2010EP2239321A1 Clearance of ras-mediated neoplastic cells from mixed cellular compositions using reovirus
10/13/2010EP2239320A1 Nerve trunk cell propagation accelerator
10/13/2010EP2239270A2 Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction
10/13/2010EP2239268A1 Dipeptide derivatives
10/13/2010EP2239265A1 Crystalline cinnamide compounds or salts thereof
10/13/2010EP2239264A1 Antitumor agent
10/13/2010EP2239261A1 Pyrrolopyrimidin derivative for use as pi3k inhibitor, and use thereof
10/13/2010EP2239254A1 Benzylpiperizine compound
10/13/2010EP2239253A1 Novel phenylpyrrole derivative
10/13/2010EP2238988A1 Conjugated prodrugs of cc-1065 analogs
10/13/2010EP2238987A1 Sugar chain-related gene and use thereof
10/13/2010EP2238985A1 High concentration antibody-containing liquid formulation
10/13/2010EP2237803A2 Treatment and prophylaxis of amyloidosis
10/13/2010EP2237786A2 Use of inhibitors of connexin43 for treatment of fibrotic conditions
10/13/2010EP1503785B1 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
10/13/2010EP1499618B1 Furyl compounds
10/13/2010EP1480644B1 Novel heterocyclic compounds which are active as inhibitors of beta+lactamases
10/13/2010EP1381631B1 Human anti timp-1 antibodies
10/13/2010EP1370537B1 Metalloproteinase inhibitors
10/13/2010EP1255553B1 Use of trilostane or keto-trilostane in combination with an antioestrogen in the treatment of a hormone-dependent condition.
10/13/2010CN1976691B Cysteamines for treating complications of hypercholesterolemia and diabetes
10/13/2010CN1646473B Novel curcumin analogues and uses thereof
10/13/2010CN1395581B Recombinant antibodies to human IL-1 beta
10/13/2010CN101861155A Electricity-generating particulates and the use thereof
10/13/2010CN101861149A N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases
10/13/2010CN101857584A Hydroxyl flavanoid compound and application thereof
10/13/2010CN101857573A Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
10/13/2010CN101856363A Application of Bortezomib in preparing drugs for curing POEMS syndrome
10/13/2010CN101632681B Glycerol fructose liposome drug combination injection and preparation method thereof
10/13/2010CN101496812B Compositional agent for rapid healing large-sized Acipenser sinensis with serious injury
10/13/2010CN101313964B Medicine for treating hydrocephalus
10/13/2010CN101087604B Medicaments for the treatment or prevention of fibrotic diseases
10/13/2010CN101081843B Non-nucleoside reverse transcriptase inhibitors
10/12/2010US7812178 such as (R)-3-(3-hydroxypyrrolidin-1-yl)-N-methyl-N-methoxypropanamide; poly(ADP-ribose)polymerase inhibitors
10/12/2010US7812044 Hormone sensitive vcancer; antiproliferative agents ; induction apoptosis; angiotensin inhibitors
10/12/2010US7812033 Method for increasing the activity of acid-β-galactosidase
10/12/2010US7812031 Pyrimidine derivatives as orexin receptor antagonists
10/12/2010US7812014 such as (5R,6Z)-6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, in combination with beta-lactam antibiotics, for the treatment of bacterial infections
10/12/2010US7811992 Measuring binding of Bradykinin and angiogensin receptor; calibration; animal hibernation
10/12/2010US7811991 Polypeptide therapeutic for treating ischemia associated with perioperative surgical procedure
10/12/2010US7811984 BV8 nucleic acids and polypeptides with mitogenic activity
10/12/2010US7811570 ablating a targeted non-malignant B cell, comprising administering to a human subject having an immune disease an unconjugated monoclonal antibody (LL2 antibody) which binds to a marker that is specific for a B cell
10/12/2010US7811566 Antibody-induced apoptosis
10/12/2010US7811557 treating a human suffering from stroke by administering directly at the site of stroke human CD 34+/-, Lin-cells from umbilical cord blood (UCB) or peripheral blood, separated from other mononuclear cells prior to use
10/12/2010CA2533919C Therapeutic agent for chronic obstructive pulmonary disease and method for treating chronic obstructive pulmonary disease using the same
10/12/2010CA2480038C Substituted 4-aminocyclohexanols
10/12/2010CA2477903C Substituted benzofurans useful as protein kinase b activators
10/12/2010CA2476164C Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity
10/12/2010CA2470578C Tetrahydroquinoline analogues as muscarinic agonists
10/12/2010CA2467838C Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
10/12/2010CA2459470C Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use
10/12/2010CA2455863C Tetrahydroquinoline derivatives as gamma secretase inhibitors
10/12/2010CA2455526C Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof
10/12/2010CA2441110C Pharmaceutical compositions for treating arteriosclerosis
10/12/2010CA2427352C Glycerophosphoinositol derivatives as modulators of cytosolic phospholipase
10/12/2010CA2419552C Substituted pyrazoles
10/12/2010CA2419205C Anti-tnf antibodies, compositions, methods and uses
10/12/2010CA2409466C High functional water containing titanium and method and apparatus for producing the same
10/12/2010CA2399161C Method for the preparation of functionalised derivated of .beta.-(1,3)-glucans
10/12/2010CA2375224C Human antithrombin variants
10/12/2010CA2365266C Soybean protein nutraceuticals
1 ... 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 ... 1564